Gastric Adenocarcinoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 30 expanded access programs, clinical trials, and compassionate use pathways listed for Gastric Adenocarcinoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with gastric adenocarcinoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 9 programs are currently active or recruiting, with the remaining 21 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Mayo Clinic, ALX Oncology Inc., Apollo Therapeutics Ltd, Banner Health, and others.
By recruiting status
Snapshot of where every Gastric Adenocarcinoma program currently sits in its lifecycle.
- Active / Recruiting9
- Inactive21
Top sponsors
Organisations running the most Gastric Adenocarcinoma programs in the directory.
- M.D. Anderson Cancer Center3 programs
- Mayo Clinic2 programs
- ALX Oncology Inc.1 program
- Apollo Therapeutics Ltd1 program
- Banner Health1 program
- Baylor College of Medicine1 program
- BigHat Biosciences, Inc.1 program
- Dan Zandberg1 program
- ECOG-ACRIN Cancer Research Group1 program
- Emory University1 program
Gastric Adenocarcinoma programs (30)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Vaccine Study for Treating Gastrointestinal Cancers — Thomas Jefferson University
- Study on Heated Chemotherapy with Cisplatin and Paclitaxel for Treating Stomach and Gastroesophageal Cancer at High Risk of Returning — Mayo Clinic
- Study on Nivolumab, Ipilimumab, and Chemoradiation for Treating Patients with Stomach Cancer That Can Be Removed by Surgery — M.D. Anderson Cancer Center
- Study on BHB810 for Advanced Stomach and Gastroesophageal Cancer — BigHat Biosciences, Inc.
- Phase II Study on Surgery and Heated Chemotherapy for Stomach Cancer — Banner Health
- Study on Tadalafil and Chemotherapy for Treatable Stomach and Gastroesophageal Cancer — University of Arizona
- Study on Adding Paclitaxel to Chemotherapy for Gastric Cancer Spread to the Abdominal Cavity — ECOG-ACRIN Cancer Research Group
- Study Comparing Standard Treatment With and Without Additional Procedures for Patients With Metastatic Upper GI Cancer and No Detectable Tumor DNA in Blood — Yale University
- Study on Tucatinib with Trastuzumab and Chemotherapy or Pembrolizumab for HER2+ Gastrointestinal Cancers — Seagen, a wholly owned subsidiary of Pfizer
- Study on VLS-1488 for Patients with Advanced Cancer — Volastra Therapeutics, Inc.
- Phase II Study of Paclitaxel and Surgery for Stomach Cancer with Spread to the Abdomen or Positive Cancer Cells — M.D. Anderson Cancer Center
- Study on Evorpacept (ALX148) for Patients with Advanced HER2+ Gastric Cancer — ALX Oncology Inc.
- Study of Pembrolizumab with Trastuzumab and Chemotherapy for Esophagogastric Cancer — Memorial Sloan Kettering Cancer Center
- A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer — Baylor College of Medicine
- Study on TRK-950 with Ramucirumab and Paclitaxel for Treating Gastric Cancer — Toray Industries, Inc
- Study on APL-5125 for Adults with Advanced Solid Tumors — Apollo Therapeutics Ltd
- Study on Anti-PD-1 Antibody with Metabolic Modulator for Treating Solid Tumors — Dan Zandberg
- Study on Chemotherapy With or Without Radiation or Surgery for Treating Esophageal or Gastric Cancer That Has Spread to Less Than 3 Places — M.D. Anderson Cancer Center
- Evaluating Novel Therapies in ctDNA Positive GI Cancers — Georgetown University
- Expanded Access Use of DKN-01 for Treating Advanced Solid Tumors — Leap Therapeutics, Inc.
- Genetic Analysis-Guided Irinotecan Dosing in Chemotherapy for Advanced Gastroesophageal or Stomach Cancer — University of Chicago
- Study on Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Cancer — University of Wisconsin, Madison
- Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer — Rutgers, The State University of New Jersey
- Phase II Study of Cabozantinib and Pembrolizumab for Advanced Stomach and Gastroesophageal Cancer — University of California, Irvine
- Study on New Treatment for Advanced Solid Tumors Resistant to Standard Therapies — Klus Pharma Inc.
- Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer — Washington University School of Medicine
- Robotic Surgery and Heated Chemotherapy for Treating Stomach Cancer with Limited Spread to the Abdominal Lining, ROBO-CHIP Study — Mayo Clinic
- Study of Suratadenoturev (OBP-301) with Pembrolizumab for Esophagogastric Cancer — Weill Medical College of Cornell University
- TAS102 in Combination With NAL-IRI in Advanced GI Cancers — Emory University
- Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy for Localized Gastric and Gastroesophageal Junction Cancer — National Cancer Institute (NCI)
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Gastric Adenocarcinoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.